Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sudocrem is a multi-ingredient topical antiseptic healing cream primarily used for the treatment of diaper rash (nappy rash) and other minor skin irritations. Originally developed in 1931 by Thomas Smith, it is currently marketed by Teva. The formulation consists of zinc oxide (15.25%), which provides a protective water-repellent barrier and has astringent properties; benzyl alcohol (0.39%), which acts as a mild local anesthetic and disinfectant; and benzyl benzoate (1.01%) and benzyl cinnamate (0.15%), which contribute to its antiseptic and healing effects. Lanolin (4%) is included as an emollient to soothe and soften the skin. It is widely available over-the-counter in the UK and Ireland for indications including eczema, bedsores, acne, and minor burns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sudocrem.